---
title: "Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: Levacetylleucine"
description: "Formulary evidence on Adrabetadex (Lembaz, VTS-270) in Infantile-onset Niemann-Pick disease type C: Levacetylleucine. Topics: Guideline recommendation: levacetylleucine for patients with neurological symptoms, Product history: first FDA approval for Niemann-Pick disease type C in 2024, Regulatory status outside the United States: European Union authorisation for Niemann-Pick disease type C, Change of ownership of the manufacturer in October 2026, and 6 further topics. 10 evidence topics quoted from 11 sources."
canonical: "https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/product-information-and-disease-description/levacetylleucine"
published: "2026-11-19T12:08:36-05:00"
modified: "2026-11-19T12:08:36-05:00"
---

# Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: Levacetylleucine

<a id="heading-2.2.2.1.2"></a>

## 2.2.2.1.2 Levacetylleucine

<a id="topic-2.2.2.1.2-1"></a>

### Guideline recommendation: levacetylleucine for patients with neurological symptoms

> “Levacetylleucine (also known as L‐acetylleucine) is a modified amino acid derivative of leucine, approved by the FDA for treating neurological manifestations of NPC in both adult and pediatric patients.”
> “Statement #16: All patients with a confirmed diagnosis of NPC and neurological symptoms should be considered for levacetylleucine therapy.”
> “Strength of recommendation: 2”
> “Expert's opinion: completely agree (41.38%), mostly agree (37.93%), partially agree (17.24%), partially disagree (3.45%), mostly disagree (0.00%), and completely disagree (0.00%).”

Source: [Hiwot et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13110917/)

<a id="topic-2.2.2.1.2-2"></a>

### Product history: first FDA approval for Niemann-Pick disease type C in 2024

> “Today, the U.S. Food and Drug Administration approved Aqneursa (levacetylleucine) for the treatment of neurological symptoms associated with Niemann-Pick disease type C (NPC) in adults and pediatric patients weighing at least 15 kilograms.”
> “The FDA granted Aqneursa Priority Review, Fast Track, Orphan Drug and Rare Pediatric Disease designations for this application.”

Source: [FDA (2024)](https://www.fda.gov/news-events/press-announcements/fda-approves-new-drug-treat-niemann-pick-disease-type-c)

| Action date | Submission | Action type | Submission classification | Review priority; orphan status |
| --- | --- | --- | --- | --- |
| “09/24/2024” | “ORIG-1” | “Approval” | “Type 1 - New Molecular Entity” | “PRIORITY; Orphan” |

Source: [Drugs@FDA NDA 219132](https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=219132)

> “Please refer to your new drug application (NDA), dated and received January 24, 2024, and your amendments, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA), for Aqneursa (levacetylleucine) for oral suspension.”

Source: [FDA NDA approval letter (2024)](https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2024/219132Orig1s000ltr.pdf)

<a id="topic-2.2.2.1.2-3"></a>

### Regulatory status outside the United States: European Union authorisation for Niemann-Pick disease type C

> “Aqneursa received a marketing authorisation valid throughout the EU on 19 January 2026.”
> “Aqneursa is a medicine used to treat neurological symptoms (symptoms affecting the brain and nerves) of Niemann-Pick type C (NPC) disease in adults and children aged 6 years and older who weigh at least 20 kg.”

Source: [European Medicines Agency Aqneursa EPAR (2026)](https://www.ema.europa.eu/en/medicines/human/EPAR/aqneursa)

| Field | Quoted record |
| --- | --- |
| EMA product number | “EMEA/H/C/006327” |
| Marketing authorisation holder | “Intrabio Ireland Limited” |
| Opinion adopted | “13/11/2025” |
| Marketing authorisation issued | “19/01/2026” |

Source: [European Medicines Agency Aqneursa EPAR (2026)](https://www.ema.europa.eu/en/medicines/human/EPAR/aqneursa)

<a id="topic-2.2.2.1.2-4"></a>

### Change of ownership of the manufacturer in October 2026

> “Japan's Shionogi stepped in to purchase IntraBio and its medicine in October.”

Source: [Fierce Pharma LEMBAZ approval report (2026)](https://www.fiercepharma.com/pharma/beren-clinches-long-awaited-fda-nod-niemann-pick-disease)

<a id="topic-2.2.2.1.2-5"></a>

### Molecular target: prescribing information

> “The distinct molecular target for levacetylleucine in the treatment of NPC or A-T is unknown.”

Source: [Aqneursa prescribing information (2026)](https://www.aqneursa.com/wp-content/prescribing-information.pdf)

<a id="topic-2.2.2.1.2-6"></a>

### Phase 2 open-label, rater-blinded trial in participants aged 6 years or older

> “In this multi-national, open-label, rater-blinded Phase II study, patients were assessed during a baseline period, a 6-week treatment period (orally administered NALL 4 g/day in patients ≥ 13 years, weight-tiered doses for patients 6–12 years), and a 6-week post-treatment washout period.”
> “33 subjects aged 7–64 years with a confirmed diagnosis of NPC were enrolled.”
> “NALL met the CI-CS primary endpoint (mean difference 0.86, SD = 2.52, 90% CI 0.25, 1.75, p = 0.029), as well as secondary endpoints.”
> “No treatment-related serious adverse events occurred.”

Source: [Bremova-Ertl et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8361244/)

<a id="topic-2.2.2.1.2-7"></a>

### Phase 3 crossover trial: design and population in the prescribing information

> “The safety and efficacy of AQNEURSA for the treatment of NPC were evaluated in a randomized, double-blind, placebo-controlled, two-period crossover study that evaluated the efficacy of AQNEURSA in 60 patients (Trial 1; NCT05163288).”
> “To be eligible for the study, patients had to be aged 4 years or older with a confirmed diagnosis of NPC.”
> “AQNEURSA and placebo were administered orally with or without food for 12 weeks in each period.”
> “The median age at treatment initiation was 25 years (range: 5 to 67 years).”
> “The majority of the patients (n=51, 85%) received miglustat treatment prior to randomization and during the trial.”
> “The estimated mean fSARA total score was 5.1 when patients were treated with AQNEURSA and 5.6 when patients were treated with placebo.”

Source: [Aqneursa prescribing information (2026)](https://www.aqneursa.com/wp-content/prescribing-information.pdf)

<a id="topic-2.2.2.1.2-8"></a>

### SARA and fSARA treatment differences in the Niemann-Pick disease type C trial of levacetylleucine

> “The primary end point was the total score on the Scale for the Assessment and Rating of Ataxia (SARA; range, 0 to 40, with lower scores indicating better neurologic status).”
> “The mean (±SD) change from baseline in the SARA total score was -1.97±2.43 points after 12 weeks of receiving NALL and -0.60±2.39 points after 12 weeks of receiving placebo (least-squares mean difference, -1.28 points; 95% confidence interval, -1.91 to -0.65; P<0.001).”

Source: [Bremova-Ertl et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38294974/)

> “The estimated treatment difference for the fSARA total score was -0.4 (95% CI: -0.7, -0.2) (Table 4).”

Source: [Aqneursa prescribing information (2026)](https://www.aqneursa.com/wp-content/prescribing-information.pdf)

<a id="topic-2.2.2.1.2-9"></a>

### Plain language summary of the phase 3 result in a state Medicaid drug evaluation

> “After 12 weeks, people taking levacetylleucine had a small improvement in some symptoms compared to people who took a placebo.”

Source: [Oregon State University Drug Use Research and Management Program (2025)](https://www.orpdl.org/durm/meetings/meetingdocs/2025_12_04/archives/2025_12_04_NDE_NiemannPickC.pdf)

<a id="topic-2.2.2.1.2-10"></a>

### Open-label extension at 12 and 18 months compared with a historical cohort

> “Fifty-three patients aged 5–67 years (45.3% female, 54.7% male) were enrolled in the EP.”
> “The mean (±SD) baseline (visit 2) score on the 5-domain NPC-CSS was 11.10 (±4.73).”
> “After 12 months, the mean (±SD) change from baseline on the 5-domain NPC-CSS was −0.27 (±2.42) with NALL vs +1.5 (±3.16) in the historical cohort (95% CI −3.05 to −0.48; p = 0.009), corresponding to a 118% reduction in annual disease progression.”
> “After 18 months, the mean (±SD) change was +0.05 (±2.95) with NALL vs +2.25 (±4.74) in the historical cohort (95% CI −4.06 to −0.35; p = 0.023).”
> “Subgroup analysis of pediatric vs adult patients demonstrated consistent benefit with NALL.”
> “No TEAEs occurred in more than 10% of patients on NALL, and no patients had TEAEs that were assessed by the investigator as related to NALL.”

Source: [Patterson et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12296777/)

## Related pages
- [Adrabetadex (Lembaz): Infantile-onset Niemann-Pick disease type C](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c.md)
- [Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: Terms and abbreviations](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/terms-and-abbreviations.md)
- [Adrabetadex (Lembaz): Infantile-onset Niemann-Pick disease type C](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/executive-summary) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/executive-summary.md)
- [Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: Product information and disease description](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/product-information-and-disease-description.md)
- [Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: Clinical evidence](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/clinical-evidence.md)
- [Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: Economic information and modeling report](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/economics) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/economics.md)
- [Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: References](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/references) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/references.md)
